drugset
drugset / Trial / NCT06163729

Camrelizumab Combined With Chemotherapy and Radiotherapy Perioperative Treatment of Esophageal Gastric Junction Adenocarcinoma

NCT06163729 ↗

Phase 2 Recruiting 68 enrolled Cancer Institute and Hospital, Chinese Academy of Medical Sciences
NaSingle-groupOpen-labelTreatment

Summary

This project intends to study the efficacy and safety of camrelizumab combined with chemotherapy followed by radiotherapy in the perioperative treatment of AEG.

Timeline

Start
2022-08-25
Primary completion
2025-05-01
Completion
2028-05-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Camrelizumab Monoclonal antibody 200 mg Intravenous
Subject Oxaliplatin Small molecule 100 mg/m2 Intravenous
Subject Paclitaxel Small molecule 125 mg/m2 Intravenous

Indications

gastroesophageal junction adenocarcinoma